Loading the records…
Loading the records…
The Stem Cell Therapeutic and Research Reauthorization Act of 2026 (S4109) was ordered favorably reported out of the Senate HELP Committee. As a reauthorization bill with no specified funding amount, it maintains existing stem cell programs but does not create new market opportunities or funding streams. No direct revenue impact on publicly traded companies is determinable from the provided text.
This bill does not alter the competitive landscape for any publicly traded healthcare company. Stem cell transplant registry operations are federally run and do not provide material contracts to commercial entities. No public company sees revenue, costs, or competitive position impacted. Investors should not expect any sector or ticker movement from this legislative action. The bill's passage is likely given bipartisan support and committee approval, but the market implications remain zero.
On June 17, 2026, the Senate Committee on Health, Education, Labor, and Pensions ordered S4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2026, to be reported favorably with an amendment. Introduced by Sen. Jack Reed (D-RI), the bill currently awaits floor action. The bill reauthorizes existing stem cell research and therapeutic programs at the federal level, primarily affecting the National Marrow Donor Program and the C.W. Bill Young Cell Transplantation Program. These programs facilitate stem cell transplants and maintain donor registries. The bill does not include a new or increased funding authorization—only extends existing authorities. No specific dollar amounts are provided in the bill summary or action history. Therefore, the financial implications for the healthcare sector are minimal at this authorization stage. The related House bill, HR5160, was also ordered reported, indicating bicameral progress but no appropriations have been made. The legislative path forward requires Senate floor passage, House passage, and reconciliation, followed by a separate appropriations process to allocate any funds. For public companies, the reauthorization maintains current contracting flows from the Department of Health and Human Services to blood banks, transplant centers, and registry operators. These contracts are typically small, operational-level agreements not material to large healthcare companies such as $JNJ, $MRK, or $PFE. No pure-play public company derives significant revenue from stem cell transplant registry operations. The bill's impact on commercial stem cell research or therapeutic development is indirect and limited to maintaining the federal research infrastructure, which has existed for years. Given the procedural nature of a reauthorization without new funding, no actionable market signal exists for retail investors.
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive orders & memoranda affecting the same sectors or companies
This executive order requires all federal contractors and subcontractors to notify the White House and relevant agencies of any congressional requests related to their work with the executive branch, and to follow instructions to withhold information deemed protected by executive privilege. It directs agencies to enforce these requirements through contract termination or debarment, and tasks the Office of Management and Budget with developing implementation guidance. The order aims to protect executive branch confidentiality and enhance efficiency in federal contracting by preventing uncoordinated disclosures to Congress.
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →